Protective effects of GM-CSF in experimental neonatal hypothyroidism

R.G. Ahmed, M. Abdel-Latif, F. Ahmed
  • International Immunopharmacology, December 2015, Elsevier
  • DOI: 10.1016/j.intimp.2015.10.001

GM-CSF & neonatal hypothyroidism

What is it about?

Hypothyroidisminduced bymethimazole (MMI), has a negative impact on the postnatal development. Neonatal GranulocyteMacrophage-Colony Stimulating Factor [GM-CSF; 50 μg/kg, intramuscular injection at postnatal day (PND) 17] had been tested to ameliorate the effects ofMMI [0.05%, (weight per volume; w/v), intraperitoneal injection at PND 15]-induced hypothyroidisminWistar rats. The hypothyroid conditions due to the administration of MMI produced inhibitory effects on neonatal serum thyroxine (T4), 3,5,3′-triiodothyronine (T3), neutrophil count in bone marrow and blood, cerebellar glutathione (GSH) and acetylcholinesterase (AchE), although it induced stimulatory actions on serum thyrotropin (TSH), growth hormone (GH), insulin growth factor-II (IGFII), tumor necrosis factor alpha (TNF-α), and cerebellar malondialdehyde (MDA) at PND 19. The treatment with GM-CSF could reverse the depressing and stimulating effects ofMMI on these markers except for cerebellar AchE where its enhancement was non-significant (P N 0.05) at tested PND. Thus, neonatal GM-CSF may be responsible for suppressing autoimmune responses and preventing hypothyroidism.

The following have contributed to this page: Dr ahmed R. G.